

---

2 December 2019

## Immunicum Article in BioStock

Immunicum was recently covered in BioStock's article, "Immunicum attacks cancer with an immune activation "bomb""

For access to the full article in **English**, click here: <http://bit.ly/34JnMGF>

For access to the full article in **Swedish**, click here: <http://bit.ly/34JnMGF>

FOR MORE INFORMATION, PLEASE CONTACT:

Carlos de Sousa, CEO, Immunicum  
Telephone: +46 8 732 8400  
E-mail: [info@immunicum.com](mailto:info@immunicum.com)

Michaela Gertz, CFO, Immunicum  
Telephone: +46 70 926 17 75  
E-mail: [ir@immunicum.com](mailto:ir@immunicum.com)

### ABOUT IMMUNICUM AB (PUBL)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. [www.immunicum.com](http://www.immunicum.com)